• MSR176 Q-Squared as a Mapping Model Performance Metric in Gastrointestinal Disease

    Dec 1, 2025, 00:00

  • MSR220 What About a Latent Cure Model? Assessing Cure Models’ Performance in Pediatric Acute Lymphoblastic Leukemia Treated With Tisagenlecleucel

    Dec 1, 2025, 00:00

  • HSD10 Assessing the Quality and Determinants of Referrals From General Practitioners (Primary Care Physicians for Adults) to Specialist Physicians in the Cyprus Healthcare System

    Dec 1, 2025, 00:00

  • CO41 Children With Asthma Receiving Dupilumab Plus Medium-Dose Inhaled Corticosteroids Had Improved Exacerbations, Lung Function, and Airway Inflammation Compared To Those Receiving Placebo Plus High-Dose Inhaled Corticosteroids

    Dec 1, 2025, 00:00

  • HSD14 Biologic Treatment Patterns and Phenotyping in Severe Uncontrolled Asthma: A Multinational Study

    Dec 1, 2025, 00:00

  • HPR215 The Value of Medical Spending in China, 1991-2019

    Dec 1, 2025, 00:00

  • RWD25 Best Practices Framework for Real-World Data (RWD) in Regulatory Submissions

    Dec 1, 2025, 00:00

  • EE164 Cost-Effectiveness Analysis of Tenecteplase vs. Alteplase for Adults With Acute Ischemic Stroke (AIS) in Greece

    Dec 1, 2025, 00:00

  • RWD59 Development and Evaluation of a Proactive Monitoring Model for Adverse Drug Events in Patients With Pulmonary Arterial Hypertension Based on the Delphi and Real-World Data

    Dec 1, 2025, 00:00

  • HTA114 Diverging Health Technology Assessment Outcomes Between SMC and HAS: A Focus on the Role of Indirect Treatment Comparisons

    Dec 1, 2025, 00:00

  • HTA336 The Value Flower in Bloom: Emerging Recognition of Uncaptured Benefits in NICE HTA Decisions

    Dec 1, 2025, 00:00

  • EE163 Cost-Effectiveness Analysis of Ribociclib With Endocrine Therapy for Treatment With Premenopausal Women With HR Positive HER2 Negative Early Breast Cancer in the UK

    Dec 1, 2025, 00:00

  • EPH233 The Epidemiology Burden and Management of Chronic Hand Eczema in Adolescents: A Systematic Literature Review

    Dec 1, 2025, 00:00

  • RWD186 Trends of Prescriptions for Medical Technologies Not Covered by the Colombian Health Benefits Package Between 2020 and 2024: A Descriptive Study

    Dec 1, 2025, 00:00

  • RWD29 Characteristics of Real-World Data Landscape in Italy: A Scoping Review

    Dec 1, 2025, 00:00

  • HTA170 Have Delays in Vaccine Market Access Improved in Europe and the US Over the Last Decade?

    Dec 1, 2025, 00:00

  • HPR84 Evolving Trends in US Healthcare Policy: Perspectives From US Formulary Decision Makers

    Dec 1, 2025, 00:00

  • EPH237 The Health Impact of Pembrolizumab for the First-Line Treatment for Metastatic Non-Small Cell Lung Cancer (mNSCLC) That Expresses High Levels of PD-L1 in Türkiye

    Dec 1, 2025, 00:00

  • EPH60 Development of a Markov Model-Based Visualization Tool of Regional HPV Vaccination Coverage Rates Over Time in Austria: Combining Data From Pharmaceutical Industry and Healthcare Data Including National Vaccination Registry

    Dec 1, 2025, 00:00

  • EE54 Application and Future Potential of Generative Artificial Intelligence (Gen AI) And Large Language Model (LLM) In Health Economics and Outcomes Research (HEOR)

    Dec 1, 2025, 00:00

  • CO184 Predictors of Postoperative Complications Following Cytoreductive Surgery With HIPEC: A Real-World Analysis of 493 Patients in Québec

    Dec 1, 2025, 00:00

  • HSD11 Assessing the Quality of Hemophilia Care: How Suitable Are Patient-Centered Outcomes to Compare Hospital Performance?

    Dec 1, 2025, 00:00

  • HTA207 Integrating Patient Perspectives Into Drug Reimbursement Decisions: Insights From Taiwan’s Deliberative HTA Process

    Dec 1, 2025, 00:00

  • CO96 Efficacy of Pregabalin and High-Concentration (179 mg) Capsaicin Patch in Peripheral Neuropathic Pain: A Review of Studies ≥ 26 Weeks' Duration

    Dec 1, 2025, 00:00

  • EE4 A Budget Impact Model of Switching From Self-Monitoring of Blood Glucose to Continuous Glucose Monitoring for Individuals With Type 2 Diabetes Mellitus Receiving Basal Insulin in Italy

    Dec 1, 2025, 00:00

  • SA72 Network Meta-Analysis of Survival Outcomes in the First-Line Treatment of Unresectable or Metastatic Melanoma: Scoping Review of Methodology

    Dec 1, 2025, 00:00

  • EE730 Thecosystem: A Systemwide Health and Social Care Decision Analytical Model to Assess Population-Based Interventions for Older People’s Care in the UK

    Dec 1, 2025, 00:00

  • EPH39 Changes in the Epidemiological Indicators of Female Infertility in Europe 1991-2021

    Dec 1, 2025, 00:00

  • EE200 Cost-Effectiveness Analysis of FreeStyle Libre Systems vs. Self-Monitoring of Blood Glucose in People With Type 2 Diabetes on Basal Insulin: An Israeli Healthcare System Perspective

    Dec 1, 2025, 00:00

  • Patient-Reported Outcomes Now and Into the Future: Multistakeholder Perspectives on Optimizing the Use of Patient-Reported Outcome Evidence in Decision Making Across the US Healthcare Continuum

    Dec 1, 2025, 00:00

  • EE147 Complement C5 Inhibitor (Anti-C5) and Neonatal Fc Receptor Antagonist Anti-FcRn in Myasthenia Gravis at University Public Hospitals of Paris, France (AP-HP): What Is the Market Share of These New Treatments?

    Dec 1, 2025, 00:00

  • PCR111 Healthcare Professionals-Perceived Benefits and Opportunities to Improve an Electronic Patient-Reported Outcomes (ePRO)-Based Remote Symptom Monitoring (RSM) Program During Cancer Treatment

    Dec 1, 2025, 00:00

  • PCR153 Meaningful Within-Patient Change of the IWQOL-Lite-CT Physical Function Composite in Adults With Obesity

    Dec 1, 2025, 00:00

  • EE614 Preventing Stunting Through Early Nutritional Intervention: Effectiveness and Economic Evaluation in Children With Weight Faltering

    Dec 1, 2025, 00:00

  • MT38 Standardizing Healthtech Evidence to Meet NICE Expectations

    Dec 1, 2025, 00:00

  • HTA355 Value Framework to Support Payer Decisions in Hemophilia in Türkiye

    Dec 1, 2025, 00:00

  • SA34 Direct Healthcare Costs (HCCs) Inequalities Associated With Myasthenia Gravis (MG) in Hungary: Claims Database Analysis

    Dec 1, 2025, 00:00

  • EE712 The Impact of Burosumab on the Clinical and Economic Burden of X-Linked Hypophosphatemia in Adult Patients in France

    Dec 1, 2025, 00:00

  • EE351 Economic and Social Burden of Pulmonary Hypertension in Italy

    Dec 1, 2025, 00:00

  • CO212 Resistance-Driven Treatment Failure: A Challenge to HCV Elimination in Pakistan

    Dec 1, 2025, 00:00

  • The Impact of the Inflation Reduction Act’s Drug Price Negotiation Program on Incentives for Clinical Development of New Drugs

    Dec 1, 2025, 00:00

  • EE305 Cost-Utility Analysis of Multiplex Cell Culture Technology for Predicting Carboplatin Plus Paclitaxel-Induced Side Effects in Cancer Care

    Dec 1, 2025, 00:00

  • RWD146 Real-World Adherence to Nonhormonal Therapies for Menopause-Related Vasomotor Symptoms: A Targeted Literature Review

    Dec 1, 2025, 00:00

  • CO103 Evaluating EU-HTA PICO Exercise Outcomes: Duration of Response and Time to Response in Hepatocellular Carcinoma Using Randomization-Preserving Methods with IMbrave150 Data

    Dec 1, 2025, 00:00

  • EPH59 Development and Validation of a Case Identification Algorithm for Hand Trauma Patients Using Health Administrative Data and the Epidemiology of Hand Trauma in a Universal Healthcare System

    Dec 1, 2025, 00:00

  • PCR207 Real-World Socioeconomic Burden and Health-Related Quality of Life (HRQoL) for Patients Living with Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) in the UK: Results From an Online Patient Survey

    Dec 1, 2025, 00:00

  • SA69 Methods for the Economic Evaluation of Health Impacts of Climate Action: When, Why, and How Best to Use Them? A Literature Review

    Dec 1, 2025, 00:00

  • P21 Real-World Evidence of Healthcare Resource Utilization in Cystic Fibrosis (CF) Patients Treated With Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) in France Using Long-term Data From the SNDS Database Linked to the French CF Registry: ...

    Dec 1, 2025, 00:00

  • EE421 Estimating Life-Years and QALYs Gained From Tumor Treating Fields in Newly Diagnosed Glioblastoma: A US-Based Real-World Survival-Based Model

    Dec 1, 2025, 00:00

  • PT33 Trends in Reimbursement Agreements for Innovative Orphan and Oncological Medicines in Spain 2020-2025

    Dec 1, 2025, 00:00

  • CO68 Data Visualization of Treatment Patterns in Adults With BRAFV600E Mutant mNSCLC in Real-World Settings

    Dec 1, 2025, 00:00

  • HSD69 Localizing a Sequencing Model Using Patient-Level Data to Optimize Outcomes in the First Line of Treatment for Multiple Myeloma in Greece

    Dec 1, 2025, 00:00

  • HTA271 Predicting PICOs for EU HTA: The Validated PICO Planner Approach Based on Retrospective Analysis

    Dec 1, 2025, 00:00

  • PCR174 Patient Perspectives on Mild-Moderate Infection Burden in Multiple Myeloma and Chronic Lymphocytic/Small Lymphocytic Leukemia

    Dec 1, 2025, 00:00

  • PCR113 Health-Related Quality of Life Among People With Arthritis in Ireland

    Dec 1, 2025, 00:00

  • HTA249 Navigating the Transition: What EU JCA Means for AMNOG Submissions in 2025 and Beyond

    Dec 1, 2025, 00:00

  • SA37 Effectiveness of Psychosocial Interventions for Adults With Substance Use Disorder and Co-Occurring Mental Health Disorder: An Umbrella Review

    Dec 1, 2025, 00:00

  • RWD57 Design Operating Characteristics in a Noninterventional Study Framework

    Dec 1, 2025, 00:00

  • PCR34 Burden of Transfusion in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH): Results From a Real-World Study in European Countries

    Dec 1, 2025, 00:00

  • EE665 Socioeconomic and Geographic Inequalities in Colorectal Cancer Care Utilization and Expenditures: A Decomposition Analysis

    Dec 1, 2025, 00:00

  • CO80 Early Life Hypoglycemia and Neurological Sequalae in Children With Congenital Hyperinsulinism

    Dec 1, 2025, 00:00

  • HTA287 Reimbursement Trends for GLP-1s and Emerging Antiobesity Drugs Across Seven Global Markets

    Dec 1, 2025, 00:00

  • HTA67 CDF or CDFoe: How Has the Cancer Drugs Fund Impacted Access to Atezolizumab for Patients With Non-Small Cell Lung Cancer in the Adjuvant Setting?

    Dec 1, 2025, 00:00

  • P61 Utilizing LLMs to Enhance Patient-Reported Outcome Measures: Application to the EQ-5D and Bolt-ons

    Dec 1, 2025, 00:00

  • EE56 Assessing Productivity in Health Technology Assessment: A Comparative Review of Human Capital and Friction Cost Approaches in Europe

    Dec 1, 2025, 00:00

  • HPR17 Advancing INN-Based Prescribing in Saudi Arabia’s Private Sector: Implications for Biologics and Biosimilars Utilization Under CHI Oversight

    Dec 1, 2025, 00:00

  • EE426 Estimating the Economic Burden of DLBCL: Developing and Testing a Cost of Disease Model

    Dec 1, 2025, 00:00

  • SA84 Screening and Diagnosis of Paroxysmal Nocturnal Hemoglobinuria in Gree Consensus Recommendations From a Multispecialty Expert Panel

    Dec 1, 2025, 00:00

  • HTA351 Use of the ESMO-Magnitude of Clinical Benefit Scale to Guide HTA Recommendations on Coverage and Reimbursement for Cancer Medicines in Ireland: A Retrospective Analysis

    Dec 1, 2025, 00:00

  • MT19 From Workshops to a Dashboard Prototype: Evaluating a Checklist Approach and User Design for Digital Health Technology Assessment

    Dec 1, 2025, 00:00

  • PCR127 Identifying Patient-Reported Outcome Measures to Capture Patients’ Experiences of Symptoms and Impacts of Myelodysplastic Syndromes (MDS)

    Dec 1, 2025, 00:00

  • EE222 Cost-Effectiveness and Budget Impact Analysis of Noninvasive Prenatal Testing (NIPT) for the Identification of Fetal Chromosomal Aneuploidies in Brazilian Private Healthcare System

    Dec 1, 2025, 00:00

  • RWD61 Development and Implementation of a Health and Well-being Index to Inform Risk Management and Patient Engagement in a Colombian Health Insurance Plan

    Dec 1, 2025, 00:00

  • EE720 The Public Health and Economic Effects of Various RSV Vaccination Strategies With RSVpreF Among Adults in France

    Dec 1, 2025, 00:00

  • EE437 Evaluating the Cost-Effectiveness of High-Dose Influenza Vaccination for Adults Aged 60 Years and Older in Austria

    Dec 1, 2025, 00:00

  • EE434 Evaluating the Budget Impact of Single Inhaler Triple Therapy (Fluticasone Furoate/Umeclidinium/Vilanterol) in Patients With Moderate to Severe Asthma in the Saudi Healthcare System

    Dec 1, 2025, 00:00

  • EPH275 Urinary Dysfunction Management in Multiple Sclerosis: A Nationwide Real-Life Analysis From the French SNDS Database

    Dec 1, 2025, 00:00

  • HSD103 Standardizing Point-of-Care mRNA-Based Gene Therapy Production in Europe: A Cost and Capacity Analysis of the Nanospresso Platform

    Dec 1, 2025, 00:00

  • HTA199 Increased Trends of Self-Optimized Submissions to NICE

    Dec 1, 2025, 00:00

  • CO110 Evaluating the Repurposing Potential of Statins: Association Between Statin Use and Cognitive Decline in Patients With Mild-to-Moderate Alzheimer’s Disease

    Dec 1, 2025, 00:00

  • EE758 Work Complexity in Adults With Phenylketonuria in Sweden in 2020

    Dec 1, 2025, 00:00

  • EPH250 The Longevity Conundrum: Population Aging in the UK

    Dec 1, 2025, 00:00

  • EE533 Impact of Higher-Valent Pediatric Pneumococcal Vaccines on Hospitalization Burden in Norway

    Dec 1, 2025, 00:00

  • EPH89 Estimating the Incidence and Prevalence of Menorrhagia in the UK Using the THIN Database

    Dec 1, 2025, 00:00

  • CO116 Expert Consensus on the Clinical and Economic Value of Advanced Wound-Care Products in Mexico: Results From a Delphi Panel

    Dec 1, 2025, 00:00

  • RWD88 Gender Inequalities in Aortic and Mitral Valve Interventions in Sweden

    Dec 1, 2025, 00:00

  • RWD34 Clinical Outcomes and Economic Burden of Acute Lower Respiratory Tract Infection-Related Hospitalizations Among Adults in the United States Post COVID-19 Pandemic

    Dec 1, 2025, 00:00

  • EE43 Advancing Cost-Effectiveness Modeling With R: A Flexible Approach for HTA Submissions

    Dec 1, 2025, 00:00

  • HPR32 Balancing Cost-Effectiveness With Societal Values: A Representative Survey of Norwegian Attitudes Toward Healthcare Resource Allocation

    Dec 1, 2025, 00:00

  • MSR183 ROBERTA on the Job: A Proof-of-Concept Study of a Customized GPT Tool for Risk-of-Bias Assessment of Randomized Clinical Trials

    Dec 1, 2025, 00:00

  • CO107 Evaluating the Health Impact of Anti-PD-(L)1 Agents for Early Stage Cancer Treatment in the Czech Republic

    Dec 1, 2025, 00:00

  • MSR78 Drifting in the Network: Catching Baseline Shifts Before They Wreck Your Network Meta-Analysis

    Dec 1, 2025, 00:00

  • HSD92 Real-World Analysis of Treatment Patterns and Disease Exacerbations Among Patients Initiating Therapy for Myasthenia Gravis

    Dec 1, 2025, 00:00

  • HPR111 Harmonization of Drug Policy and Regulation Across Europe: A Comparison Between the European Medicines Agency and the European HTA Regulation

    Dec 1, 2025, 00:00

  • OP9 Gatekeepers of Scien Evolving Publishing Policies in the Age of AI

    Dec 1, 2025, 00:00

  • EPH169 Negative Symptoms in Schizophrenia: An Observational Study of Patient Characteristics Cost and Healthcare Resource Utilization From a US Healthcare Database

    Dec 1, 2025, 00:00

  • MSR21 AI-Assisted Systematic Literature Screening According to NICE, UK, and CDA (Canada) Position Papers: An HTA Submission Use Case

    Dec 1, 2025, 00:00

  • MSR83 Eliciting Patients' and Clinicians' Preferences on Adjuvant Treatment for HR+/HER2- Early Breast Cancer: Design of a Probabilistic Threshold Technique in Italy

    Dec 1, 2025, 00:00

  • RWD36 Clinical Humanistic and Economic Burden Menopause-Related Vasomotor Symptoms: A Targeted Literature Review

    Dec 1, 2025, 00:00

  • Reviewer Acknowledgment

    Dec 1, 2025, 00:00

  • EE604 Organizational Budget Impact Analysis of the Port-Delivery Platform With SUSVIMO in Age-Related Macular Degeneration (AMD) in France

    Dec 1, 2025, 00:00

  • MSR58 Comparing Individualized Treatment Effect Inference Methods Through a Simulation Study

    Dec 1, 2025, 00:00

  • EE402 Economic Model of Alzheimer's Disease That Incorporates the Uncertainty Associated With Measuring Efficacy in Clinical Trials

    Dec 1, 2025, 00:00

  • PCR152 Mapping the Rare Disease Diagnostic Odyssey of Today: An Adapted Targeted Literature Review (ATLR)

    Dec 1, 2025, 00:00

  • EE671 Stakeholder Engagement in the Economic Evaluation of Site-Specific Wastewater-Based Surveillance for Preventing COVID-19 Outbreaks in Long-Term Care Facilities

    Dec 1, 2025, 00:00

  • PCR192 Productivity Impacts and the Need for Carer Support in Obstructive HCM: A Patient and Carer Survey

    Dec 1, 2025, 00:00

  • HPR61 Do Health Technology Assessments (HTA) Consider Racial Health Inequalities? A Case Study of NICE HTAs for Chronic Kidney Disease Hypertension and Diabetes

    Dec 1, 2025, 00:00

  • EE423 Estimating the Broader Societal Impact of Ocrelizumab for Multiple Sclerosis (MS) in Latin America (LATAM) Using a Social Impact Approach

    Dec 1, 2025, 00:00

  • EE453 Expanded Access to Oncology Therapies in Mexico: The Role of Bioequivalent Abiraterone and Axitinib

    Dec 1, 2025, 00:00

  • MSR110 Flexible Parametric Inference for Cause-Specific Hazard-Competing Risk Models Under Interval Censoring

    Dec 1, 2025, 00:00

  • EE607 Persistence to Basal Insulin and Economic Outcomes Among Patients With Type 2 Diabetes: A Retrospective Analysis Using Electronic Health Records in England

    Dec 1, 2025, 00:00

  • PCR13 Adherence to Anti-VEGF Treatment of Patients With Age-Related Macular Degeneration of Exudative Type (nAMD) and Diabetic Macular Edema (DME) in Gree Evidence From an Expert Panel

    Dec 1, 2025, 00:00

  • RWD145 Real-World Insights From the LOGEX IMID Observatory: A Multicountry, Multiyear Analysis of Treatment Pathways and Healthcare Resource Utilization in Immune-Mediated Inflammatory Diseases

    Dec 1, 2025, 00:00

  • HSD110 The Role of a Functional Clinical Staff in Guiding High-Cost Drug and Novel Technology Decision Making: Experience From a Latin American Oncology Clinic

    Dec 1, 2025, 00:00

  • EE252 Cost-Effectiveness of Genetic Testing for Optimizing Warfarin Therapy in Mechanical Heart Valve Patients: Insights From Qatar

    Dec 1, 2025, 00:00

  • RWD16 An AI-Powered Tool to Identify and Assess Fit-for-Use Registries for Drug Development and Evaluation

    Dec 1, 2025, 00:00

  • HPR178 Revisiting the Willingness-to-Pay Threshold in the Czech Republic: Integrating QALY Shortfall to Reflect Disease Severity and Unmet Medical Need

    Dec 1, 2025, 00:00

  • CO2 A Systematic Literature Review and Meta-Analysis Comparing Robotic-Assisted Mitral Valve Repair Using the Da Vinci Surgical System to Open Mitral Valve Repair

    Dec 1, 2025, 00:00

  • EE184 Cost per Responder Analysis of Certolizumab Pegol vs. Adalimumab in Patients With Moderate to Severe Active Rheumatoid Arthritis and High Rheumatoid Factor Levels: A Payer Perspective From France, Germany, Italy, and United Kingdom

    Dec 1, 2025, 00:00

  • EE321 Design and Early Insights From the Pre-HDBOI Study: A Multicountry Real-World Assessment of the Burden in Pre-Motor Manifest Huntington’s Disease

    Dec 1, 2025, 00:00

  • EE556 Inpatient Cost of Managing Adverse Events (AEs) Associated With Immune Checkpoint Inhibitors (ICI) Approved for Advanced or Metastatic Cancers in the UK

    Dec 1, 2025, 00:00

  • HPR209 The New Avenue for Access? European Market Access Routes Outside Traditional Public Payer Pathways

    Dec 1, 2025, 00:00

  • RWD179 The Burden and Management of Flares Among Pregnant Patients With Generalized Pustular Psoriasis (GPP): Real-World Evidence (RWE) From the Global SCRIPTOR Study

    Dec 1, 2025, 00:00

  • P39 Seeking Patient and Public’s Opinions to Determine Target Differences in Clinical Trials: A Scoping Review of Elicitation Methods

    Dec 1, 2025, 00:00

  • PT32 Can Adalimumab Serve as Big Mac Index for Pharmaceutical Prices?

    Dec 1, 2025, 00:00

  • PCR229 The Effects of Disease Modifying Anti-Rheumatic Drugs (DMARDs) on Patient-Reported Outcomes in Rheumatoid Arthritis: A Systematic Review and Network Meta-Analyses

    Dec 1, 2025, 00:00

  • HTA303 Structural Uncertainty (SU) in Model-Based Economics Appraisal (MBEA): A Document Review of the French National Authority for Health (HAS)

    Dec 1, 2025, 00:00

  • MSR173 Projected Rapid-Growing Economic Burden of Chronic Respiratory Multimorbidity in Singapore: Unveiling Diagnostic Gaps and Asian Phenotypes Through Health Administrative Data

    Dec 1, 2025, 00:00

  • EPH91 Evaluate the Statistical Utility After Transformation of a CDISC SDTM Database Into OMOP CDM

    Dec 1, 2025, 00:00

  • EPH85 Estimating Rare Disease Incidence and Prevalence of Essential Thrombocythemia in Major Health Plans in the United States

    Dec 1, 2025, 00:00

  • EE443 Evaluating the Economic Value of First-Line (1L) Treatment Strategies for Locally Advanced or Metastatic Urothelial Carcinoma (la/mUC): Insights From the Portuguese Healthcare System

    Dec 1, 2025, 00:00

  • HTA367 What Is the Impact of Patient Voice on NICE Recommendations for Drugs Assessed in 2024?

    Dec 1, 2025, 00:00

  • PCR223 Taking an Equity Lens to Patient-Reported Outcomes and Experiences in Wales Using PROGRESS PLUS: A Population-Based Cross-Sectional Study

    Dec 1, 2025, 00:00

  • HPR160 Physicians' and Pharmacists’ Views on Implementing Generic Medicines Standard and Biosimilar Guide

    Dec 1, 2025, 00:00

  • CO75 Disease Progression Modeling for an Ultra-Rare Disease: Lysosomal Acid Lipase Deficiency (LAL-D)

    Dec 1, 2025, 00:00

  • PCR212 Satisfact-Home: Perception of Care Quality and Quality of Life in Patients With Solid Tumors Receiving Immune Checkpoint Inhibitors (ICIs) Therapy From Hospital To Home: A French Multicenter Prospective Observational Study

    Dec 1, 2025, 00:00

  • PCR197 Psychometric Validation of the Mucopolysaccharidosis Health Assessment Questionnaire (MPS-HAQ) for Mucopolysaccharidosis IVA

    Dec 1, 2025, 00:00

  • Cost-Effectiveness of Interventions Addressing Loneliness Among Adults: A Systematic Literature Review

    Dec 1, 2025, 00:00

  • HTA167 Guidelines for Health Technology Assessment Ministry of Health Sultanate of Oman

    Dec 1, 2025, 00:00

  • HTA266 Patient Preference Studies in HTA for Rare Diseases: A Cross-Country Analysis of EU-4, UK, and Canada

    Dec 1, 2025, 00:00

  • EE91 Budget Impact Analysis of Noninvasive Tests Strategies for Metabolic Dysfunction-Associated Steatohepatitis (MASH) Diagnosis in Japan

    Dec 1, 2025, 00:00

  • EE573 Markov Model-Based Cost-Effectiveness Evaluation of ROSA® vs. Manual Total Knee Arthroplasty: Sweden Payer Perspective

    Dec 1, 2025, 00:00

  • PT19 Can Estimands Support Aligned Evidence Generation for EU HTA? Reflections on Their Role in Joint Clinical Assessments, PICO Alignment, and Beyond

    Dec 1, 2025, 00:00

  • P19 Treatment Burden and Quality of Life in Patients With nAMD and DME in Colombia: A Mixed Methods Study

    Dec 1, 2025, 00:00

  • HTA76 Clinical Evidence Quality in Appraisals of Drugs for Rare Diseases in England and Germany

    Dec 1, 2025, 00:00

  • EE440 Evaluating the Economic Benefit of Improved High-Dose Influenza Vaccine Coverage in the Elderly Population of Tokyo, Japan

    Dec 1, 2025, 00:00

  • RWD168 Risk of Abdominal Hernia Repair in Patients With Intestinal Stoma in Italy: A Real-World Analysis

    Dec 1, 2025, 00:00

  • EE555 Inpatient Burden of Influenza and Influenza-Like Illness Among Adults Aged 60 and Older in Germany 2019-2024

    Dec 1, 2025, 00:00

  • RWD5 A Real-World Survey of Healthcare Resource Utilization Treatment Usage and Unmet Need for Hemophilia Patients in Spain

    Dec 1, 2025, 00:00

  • MSR27 Analysis and Characterization of Variations in Conceptual and Operational Definitions for GLP-1 Agonist Treatment Eligibility for Weight Management

    Dec 1, 2025, 00:00

  • HPR23 Analysis of Clinical and Economic Evidence Focused on RWE in Medicare Drug Price Negotiations: Sacubitril/Valsartan, Rivaroxaban, and Apixaban

    Dec 1, 2025, 00:00

  • EPH226 Tendencies in the Public-Funded Hungarian One-Day Surgical Care

    Dec 1, 2025, 00:00

  • EPH188 Prevalence and Overlap of Overweight/Obesity Type 2 Diabetes and Metabolic Dysfunction-Associated Liver Disease in England: A Clinical Practice Research Datalink Study

    Dec 1, 2025, 00:00

  • EE564 Lessons From the NHS AI Awards: Experience of Evaluating AI Tools in Real-World Environments

    Dec 1, 2025, 00:00

  • EE572 Mapping the Use of Capability Measures ICECAP-A and O in Economic Evaluations

    Dec 1, 2025, 00:00

  • MSR226 Workforce Matters: Defining Labor Input for Better Health Technology Assessment

    Dec 1, 2025, 00:00

  • EE75 Bimekizumab’s Synergistic Economic Impact Across Four Indications in France

    Dec 1, 2025, 00:00

  • EE648 Repeated Breast Surgery After a Lumpectomy in England

    Dec 1, 2025, 00:00

  • EPH141 Incidence and Treatment of Squamous-Cell Anal Cancer (SCAC) in Germany: A Retrospective Study in German Statutory Health Insurance (SHI) Claims Data

    Dec 1, 2025, 00:00

  • HPR169 Randomized Controlled Trials (RCTs) Are the Gold Standard: Are They Always Used?

    Dec 1, 2025, 00:00

  • EE332 Direct Economic Impact of Idiopathic Pulmonary Fibrosis on the Brazilian Private Healthcare System: A Real-World Data Analysis

    Dec 1, 2025, 00:00

  • EE258 Cost-Effectiveness of Levofloxacin for Tuberculosis Prevention in MDR/RR-TB Contacts in High-Burden Settings

    Dec 1, 2025, 00:00

  • HPR50 Comparison of Alignment Between EMA Indications and National Reimbursement Decisions in Italy for Orphan Drugs

    Dec 1, 2025, 00:00

  • RWD15 Air Pollution Signals and National Demand for Asthma Medication in Brazil Between 2018-2023: Should It Be Considered a Public-Health Concern?

    Dec 1, 2025, 00:00

  • CO213 Review of Index Line Selection Methods in Hemato-Oncology Externally Controlled Trials: A Secondary Analysis of the Hermans et al Systematic Review

    Dec 1, 2025, 00:00

  • CO156 Investigating Composite Response Definitions Based on Key Surrogate Markers for Predicting Clinical Outcomes in Primary Biliary Cholangitis: A Systematic Review and Meta-Analysis

    Dec 1, 2025, 00:00

  • PCR171 Patient Involvement in Health Technology Assessment: A Global Review of Practices, Purposes, and Pathways

    Dec 1, 2025, 00:00

  • EE558 Integrating Stakeholder Willingness-to-Pay Using the Van Westendorp Price Sensitivity Meter Into Cost-Effectiveness Analysis: A Mixed-Methods Pricing Framework

    Dec 1, 2025, 00:00

  • EE567 Live Attenuated Influenza Vaccination (LAIV) for the Prevention of Influenza Illness in Sweden: A Cost-Effectiveness Analysis

    Dec 1, 2025, 00:00

  • HPR205 The Implementation of the European Charter of Patients’ Rights in Hungarian and Romanian Healthcare Legislation With Special Emphasis on Informed Consent

    Dec 1, 2025, 00:00

  • HPR4 A Comparative Analysis of Regulatory Divergence in Expedited Oncology Approvals: Evidence, Pathways, and Timelines Across FDA, EMA, TGA, and PMDA

    Dec 1, 2025, 00:00

  • HSD56 Healthcare Costs in Older Adults: XGBoost, NNA, and Logit

    Dec 1, 2025, 00:00

  • EE127 Clinical and Economic Benefits of Extended-Release Metformin In Prediabetes Management

    Dec 1, 2025, 00:00

  • CO143 Importance of Adjudication Committees in Retrospective Chart Review Studies for Outcomes Event Data Collection

    Dec 1, 2025, 00:00

  • HPR168 Quo Vadis? The Emerging Role of the Medicines and Healthcare Products Regulatory Agency (MHRA) in an Evolving Regulatory Landscape

    Dec 1, 2025, 00:00

  • MSR29 Application of Network Meta-Analysis in Vaccine Research: An Illustration Using Immunogenicity of Pneumococcal Vaccines in Adults

    Dec 1, 2025, 00:00

  • HSD76 Modeling the Environmental and Cost Impact of a Novel Detergent in NHS Endoscope Reprocessing Workflows

    Dec 1, 2025, 00:00

  • EPH191 Prevalence of Migraine in India: A Meta-Analysis With Subgroup Analyses by Population Type

    Dec 1, 2025, 00:00

  • CO236 The Clinical Burden and Complications Associated With Glycogen Storage Disease Type Ia (GSDIa): Results From a Systematic Literature Review

    Dec 1, 2025, 00:00

  • PCR49 Comparing Health-Related Quality of Life in Obese Patients With and Without Bariatric Surgery: A Cross-Sectional Study in a Multi-Ethnic Asian Population in Singapore

    Dec 1, 2025, 00:00

  • MSR139 Long-Term Quality-Adjusted Time Without Symptoms or Toxicity (Q-TWiST): Investigating a Parametric Survival Model for Extrapolations

    Dec 1, 2025, 00:00

  • HPR238 What Does the New ILAP Refresh Mean for Pharmaceutical Development and Patient Access in the UK?

    Dec 1, 2025, 00:00

  • HTA155 From License to Reimbursement: A Slot-Based ML Framework for Seamless MA to HTA Alignment

    Dec 1, 2025, 00:00

  • RWD43 Comprehensive Landscape Assessment of Real-World Databases for HEOR Studies in the Asia-Pacific Region: A Growing Opportunity

    Dec 1, 2025, 00:00

  • CO193 Psychometric Evaluation of the HFDD, PROMIS SD SF 8b, and MENQOL for Vasomotor Symptoms Caused by Endocrine Therapy: Reliability, Validity, and Differential Item Functioning

    Dec 1, 2025, 00:00

  • EE654 Risk, Time in Hospital, and Associated Costs? of Hospitalizations in Individuals With Infantile-Onset SMA: Results From DEVOTE Part B

    Dec 1, 2025, 00:00

  • EE550 Increased Healthcare Resource Utilization Among Uncontrolled vs. Controlled Hypertension Population: Findings From the EnligHTN Study

    Dec 1, 2025, 00:00

  • CO147 Improving Pulmonary Tuberculosis Treatment Outcomes Through Pharmacist-Led Education: Findings From a Malaysian Randomized Control Trial

    Dec 1, 2025, 00:00

  • CO76 Does the Abortion Pill Harm Women? Serious Adverse Events Following Mifepristone Abortion in US Commercial and Medicaid Populations

    Dec 1, 2025, 00:00

  • EPH63 Disease Burden of MASH/MASLD Among People With Obesity in China, Japan, and EU5

    Dec 1, 2025, 00:00

  • HPR240 Who Pays the Price? International Impacts of US Drug-Cost Benchmarking

    Dec 1, 2025, 00:00

  • CO55 Comparative Efficacy and Safety of Delgocitinib, Alitretinoin, and PUVA in Patients With Moderate-to-Severe Chronic Hand Eczema: A Network Meta-Analysis

    Dec 1, 2025, 00:00

  • CO86 Effectiveness of Pneumococcal Vaccines in Preventing Otitis Media in Children: A Targeted Literature Review

    Dec 1, 2025, 00:00

  • EE125 Climate Impact of CAR-T Cell Therapy in the Netherlands: A Comparison on the Use Phase Emission Between Standard of Care and CAR-T Cell Therapy in Hemato-oncology

    Dec 1, 2025, 00:00

  • HTA3 A Comparison of the NICE HST Program With Health Technology Assessments of Ultra-Orphan Drugs From France and Germany

    Dec 1, 2025, 00:00

  • PCR76 EQ-5D Utility Trends in NMOSD: Impact of Time and Disability

    Dec 1, 2025, 00:00

  • EPH183 Postherpetic Neuralgia Occurrence and Herpes Zoster Recurrence in Immunocompromised Adults Aged 18 Years or Older in England: A Large Retrospective Cohort Study (Clinical Practice Research Datalink 2012-2019)

    Dec 1, 2025, 00:00

  • CO195 Qualitative Exit Interviews in Charcot-Marie-Tooth Type-2 Sorbitol Dehydrogenase (CMT-SORD) Deficiency

    Dec 1, 2025, 00:00

  • HTA185 HTA for Obesity and T2DM Indications: A Review and Recommendations for Future Appraisals

    Dec 1, 2025, 00:00

  • EPH253 The Relevance of the Use of TENS Devices in the Therapy of Poststroke Dysphagia

    Dec 1, 2025, 00:00

  • PCR225 The Burden of Cognitive Impairment Associated With Schizophrenia (CIAS) on People With Lived Experience (PWLE): A National Canadian Survey

    Dec 1, 2025, 00:00

  • HPR164 Prices And Reimbursement Conditions for Poly (ADP-RIBOSE) Polymerase Inhibitors (PARPi) Indicated for Ovarian Cancer in Spain

    Dec 1, 2025, 00:00

  • SA49 Health-Related Quality of Life Impacts of Living With Primary Lateral Sclerosis (PLS): The Development of a Conceptual Model

    Dec 1, 2025, 00:00

  • MSR192 Survival Model Uncertainty in Economic Modeling: Evaluating Bootstrap and Cholesky Decomposition Methods

    Dec 1, 2025, 00:00

  • EE49 An Interactive R-Shiny Application for Budget Impact Modeling of Cell and Gene Therapies With Multiple Innovative Payment Scenarios

    Dec 1, 2025, 00:00

  • PCR187 Population-Level Impact of Emicizumab in Algeria: A 25-Year Projection

    Dec 1, 2025, 00:00

  • EE130 Clinical and Economic Impact of Early Treatment in Relapsing Remitting Multiple Sclerosis With High-Efficacy Disease-Modifying Therapy in Mexico

    Dec 1, 2025, 00:00

  • EPH40 Characterizing the Use of Janus Kinase Inhibitors (JAKi) in Five European Countries: A Drug Utilization Study

    Dec 1, 2025, 00:00

  • HTA97 Cost-Effectiveness Modeling Challenges and Trends in the Neoadjuvant and Perioperative Settings: A Review of NICE Oncology Submissions

    Dec 1, 2025, 00:00

  • CO258 US Population-Level Clinical Impact of Lorlatinib Treatment on ALK+ Metastatic Non-Small Cell Lung Cancer Outcomes

    Dec 1, 2025, 00:00

  • HPR65 Early Access Programs and Pricing and Reimbursement Agreements in Portugal for Orphan Medicines Centrally Approved in the European Union

    Dec 1, 2025, 00:00

  • EE563 Launch Price Dynamics of Targeted Therapies in NSCLC: Dissecting the Cost and Value Across Biomarker Segments

    Dec 1, 2025, 00:00

  • PCR208 Registry Participation in Rare Diseases: Insights from Stakeholders and an Adapted Targeted Literature Review (ATLR)

    Dec 1, 2025, 00:00

  • PCR233 The Impact of Treatment Compliance on Healthcare Resource Utilization Amongst Kidney Transplant Recipients: Results From a Real-World Survey

    Dec 1, 2025, 00:00

  • SA70 Modeling the Lifetime Effects of Lecanemab in Early Alzheimer’s Disease

    Dec 1, 2025, 00:00

  • RWD151 Real-World Effectiveness of Biologic Treatments for Moderate-to-Severe Atopic Dermatitis in Poland in Comparison With Efficacy Reported in Clinical Trials

    Dec 1, 2025, 00:00

  • EE647 Relationship Between Cost-Effectiveness Threshold and Drug Reimbursement in Spain, Italy, and France

    Dec 1, 2025, 00:00

  • SA94 The Impact of Early Antibacterial Therapy on ICU Patient Outcomes for Sepsis: A Causal Analysis

    Dec 1, 2025, 00:00

  • EE172 Cost-Effectiveness of Sulopenem vs. Ciprofloxacin for the Treatment of Uncomplicated Urinary Tract Infections in Women: A Decision Analysis

    Dec 1, 2025, 00:00

  • HSD89 Population-Level Impact Assessment of the Revised Dyslipidemia Prescription Protocol in Greece Using Simulation Modeling

    Dec 1, 2025, 00:00

  • HTA141 Evolving Assumptions on Treatment Durability in Cost-Effectiveness Models of Cell and Gene Therapies: Insights From French HTA Submissions

    Dec 1, 2025, 00:00

  • HPR211 The Next Steps Matter? New Cancer Medicines and Their Indication Extensions in Europe 2010-2020

    Dec 1, 2025, 00:00

  • HTA90 Consideration of Off-Label Therapies as Appropriate Comparator Therapy in Early Benefit Assessments in Germany Under the ALBVVG Legislation

    Dec 1, 2025, 00:00

  • P56 An Early Start: Preliminary Indirect Treatment Comparison Assessments Informing Evidence-Generation Planning for Joint Clinical Assessment

    Dec 1, 2025, 00:00

  • RWD84 Feasibility Assessment of Real-World Data for Trial Emulations: A Methodological Framework

    Dec 1, 2025, 00:00

  • EPH210 Sedative-Hypnotic Drug Use and Polypharmacy Patterns Associated With Risk of Falls and Fractures in Older Adults by Osteoporosis Status: A Korean Nationwide Senior Cohort Study

    Dec 1, 2025, 00:00

  • PCR31 Bimekizumab Demonstrated Sustained Long-Term Improvements in Health-Related Quality of Life and Work Productivity in Patients With Active Psoriatic Arthritis: 3-Year Results from Two Phase 3 Studies

    Dec 1, 2025, 00:00

  • MSR115 Generation of Synthetic Patient Data to Overcome Machine Learning Limitations in Healthcare Research: A Systematic Review of Methods, Performance, and Use Cases

    Dec 1, 2025, 00:00

  • EPH8 A Retrospective Study of Treatment Use in Metastatic Colorectal Cancer (mCRC) Based on French Hospital Discharge Database

    Dec 1, 2025, 00:00

  • HTA286 Reimbursement Trends for Advanced Therapeutic Medicinal Products (ATMPs) in Europe

    Dec 1, 2025, 00:00

  • MSR134 Interpreting PRO-CTCAE Data: Defining and Answering the Right Questions

    Dec 1, 2025, 00:00

  • EE639 Real-World Healthcare Resource Utilization in Patients With Metastatic Colorectal Cancer Treated With Trifluridine/Tipiracil Plus Bevacizumab or With Regorafenib

    Dec 1, 2025, 00:00

  • EE661 Societal and Economic Impact of Targeted Therapy for Breast Cancer in Bulgaria

    Dec 1, 2025, 00:00

  • PCR172 Patient Involvement in the Development of Obesity and Weight Loss-Specific Patient-Reported Outcome Measures

    Dec 1, 2025, 00:00

  • HTA222 Life-Years Lost Due to Regulatory and Reimbursement Delays: A Study of Oncology Drugs Across England, Scotland, and France, 2022-2024

    Dec 1, 2025, 00:00

  • HPR94 Feasibility of Indication-Specific Pricing for Life Cycle Management of an Innovative Rare Disease Product

    Dec 1, 2025, 00:00

  • HPR228 Understanding the Impact of Cost-Effectiveness Evaluations on Drug Pricing in Japan: A Case Study of Oncology Therapies

    Dec 1, 2025, 00:00

  • EPH142 Incidence of Intracerebral Hemorrhage in Patients With Mild Cognitive Impairment or Alzheimer’s Dementia Among United States Medicare Beneficiaries

    Dec 1, 2025, 00:00

  • CO16 Assessing the Real-World Impact of Earlier Initiation of Anti-Tumor Necrosis Factor vs. Conventional Synthetic DMARDs on Clinical and Patient-Reported Outcomes in Patients With Rheumatoid Arthritis in Europe

    Dec 1, 2025, 00:00

  • PCR248 Treatment Patterns and Healthcare Resource Utilization Among Patients With Immune Thrombocytopenia: A Real-World Survey

    Dec 1, 2025, 00:00

  • P47 Quality of Life and Utility Values Across the Alzheimer’s Disease Spectrum: Results From the What Matters Most Survey

    Dec 1, 2025, 00:00

  • EE158 Cost Calculator of Immunotherapies in 1L Endometrial Cancer Treatment for the Deficient Mismatch Repair, Proficient Mismatch Repair, and Intention-to-Treat Populations From the Brazilian Private Healthcare System

    Dec 1, 2025, 00:00

  • HTA158 From Theory to Practi Guidance for Identifying and Selecting Mapping Algorithms for Health Economic Models

    Dec 1, 2025, 00:00

  • HTA31 Analysis of HTA Decisions in Five European Countries for High Medical Need Products Approved by EMA

    Dec 1, 2025, 00:00

  • EE215 Cost-Effectiveness Analysis of Pediatric and Adult Pneumococcal Conjugate Vaccine Strategies in Canada

    Dec 1, 2025, 00:00

  • HTA161 German Early Benefit Assessments and the Impact of Medical Societies: An Analysis

    Dec 1, 2025, 00:00

  • HPR172 Registration and Access to Orphan Medicines in Türkiye: A Comparative Study With Poland and Germany

    Dec 1, 2025, 00:00

  • HTA213 Italian Perspective on Rare Disease New Treatments and HTA: Insights From Iptacopan Multidimensional Evaluation in PNH

    Dec 1, 2025, 00:00

  • CO191 Prognostic Factor Evaluation for Clinical Outcomes in HER2-Mutant NSCLC

    Dec 1, 2025, 00:00

  • EE395 Economic Evaluations Cost and Resource Utilization in Early Triple-Negative and Low Hormone Receptor-Positive Breast Cancer: A Comprehensive Systematic Review

    Dec 1, 2025, 00:00

  • HSD35 Disability Resource Utilization and Caregiver Support Among a Real-World Sample of Patients With Transthyretin Amyloidosis With Polyneuropathy

    Dec 1, 2025, 00:00

  • EPH24 Associations Between Waiting Time and Treatment Completion Among Treatment-Naive Pregnant Cannabis Users Admitted to Treatment Facilities in the United States

    Dec 1, 2025, 00:00

  • EE42 The Value of Investing in Innovative Medicines: A Scalable Approach to Measure the Lifetime Social Impact

    Dec 1, 2025, 00:00

  • CO99 Epidemiology Treatment Patterns and Outcomes in Gestational Trophoblastic Neoplasia: A Systematic Literature Review and Gap Analysis

    Dec 1, 2025, 00:00

  • EPH95 Evaluation of Safety Signal Management in Europe: Insights From PRAC Reports (2016-2024)

    Dec 1, 2025, 00:00

  • EE733 Transfusion-Related Cost and Time Burden in JAKi-Naïve and JAKi-Experienced Patients With Myelofibrosis Treated With Momelotinib and Ruxolitinib From the SIMPLIFY 1 and 2 Studies: A Brazilian Supplementary Health Perspective

    Dec 1, 2025, 00:00

  • PCR100 From Pain to Patient Preferences Patient Engagement in Early HTA for Repurposing Losartan in Osteogenesis Imperfecta

    Dec 1, 2025, 00:00

  • EE347 Early Economic Modeling of Mutant TNF (mutTNF) As a BBB-Permeabilizing Adjunct in Breast Cancer Brain Metastases: A UK NHS Perspective

    Dec 1, 2025, 00:00

  • SA101 Using a Large Language Model (LLM) for Data Extraction of Studies: Learnings From a Targeted Literature Review (TLR) in Non-Small Cell Lung Cancer (NSCLC)

    Dec 1, 2025, 00:00

  • EE340 Do We Need to Measure Social Impact of Innovative Drugs?

    Dec 1, 2025, 00:00

  • SA4 A Systematic Literature Review of Prognostic Factors in Advanced Merkel Cell Carcinoma

    Dec 1, 2025, 00:00

  • PCR110 Health Utility Values in Adults With Primary Biliary Cholangitis: A Global Systematic Literature Review

    Dec 1, 2025, 00:00

  • PCR147 Is There a Lack of Dietary Data Collection in Real-World IBD Studies? Literature Review and Future Considerations

    Dec 1, 2025, 00:00

  • EE211 Cost-Effectiveness Analysis of Lebrikizumab vs. Alternative Biologics in Adults and Adolescents With Moderate-to-Severe Atopic Dermatitis in the UK

    Dec 1, 2025, 00:00

  • RWD140 Real-World Effectiveness of Immune Checkpoint Inhibitors Chemotherapy (ICI+CT) vs. ICI Monotherapy (ICI) in Untreated Locally Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC): A Targeted Literature Review

    Dec 1, 2025, 00:00

  • EPH31 Budget Impact of an Organized Diabetes Screening in High-Risk Populations in France

    Dec 1, 2025, 00:00

  • P26 Approximating Competing Risk Events From Published Kaplan-Meier Curves Using Simultaneity-Based Event Assignment Methods

    Dec 1, 2025, 00:00

  • HTA289 Review of Surrogate Endpoints’ Acceptance Trends in German HTA and Implications for EU Joint Clinical Assessment

    Dec 1, 2025, 00:00

  • EE476 Forecasting the Rise in Direct and Indirect Costs for Lung Cancer on the Example of Poland

    Dec 1, 2025, 00:00

  • HSD16 Burden of Disease and Healthcare Resource Use in Patients With Hereditary Transthyretin Amyloidosis in Spain: Findings From the OverTTuRe Global Study

    Dec 1, 2025, 00:00

  • PCR101 Gaps in Evidence on Burden and HRQoL in Small-Cell Lung Cancer: Findings From a Targeted Literature Review

    Dec 1, 2025, 00:00

  • EE129 Clinical and Economic Burden Imposed by Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM) in Belgium

    Dec 1, 2025, 00:00

  • EE700 The Economic Burden of Inflammatory Arthritis: A Systematic Review

    Dec 1, 2025, 00:00

  • MSR43 Automation-Only Is NOT AI: Beware, HEOR Colleagues

    Dec 1, 2025, 00:00

  • HPR47 Comparative Analysis of Adult Vaccination Programs and HTA of Vaccines Approaches in the US, UK, and Fran Lessons for Poland

    Dec 1, 2025, 00:00

  • MSR205 Transportability of Overall Survival Estimates From the United States to Germany in eGFR+ Advanced NSCLC Patients Post-Tyrosine Kinase Inhibitor (TKI) Treatment

    Dec 1, 2025, 00:00

  • EPH163 Modeling the Public Health Impact of Nirsevimab and Maternal Vaccination With RSVpreF Against Infant Respiratory Syncytial Virus Infection in Germany

    Dec 1, 2025, 00:00

  • EE401 Economic Impact of Poison Control Center Interventions on Hospitalization Costs in Algeria: A Retrospective Analysis

    Dec 1, 2025, 00:00

  • RWD152 Real-World Evidence From Community Oncology: Assessing Secular Trends in Ovarian Cancer Diagnoses From 2014 to 2024

    Dec 1, 2025, 00:00

  • HTA284 Reimbursement Challenges for ATMPs in EU5: Learnings From Product Withdrawals and Implications for Future Development of Innovative Therapies

    Dec 1, 2025, 00:00

  • EE338 Do Public Preferences Matter? Health-Economic Evaluation of Antineoplastic Medication Considering EQ-5D Value Sets From Several Countries

    Dec 1, 2025, 00:00

  • HPR139 Maximizing Profits Through Pricing: Opportunities in Portugal's Pharma Sector

    Dec 1, 2025, 00:00

  • CO254 Treatment Response in Pediatric Patients With Status Epilepticus: A Retrospective Observational Study From Saudi Arabia

    Dec 1, 2025, 00:00

  • EE430 Evaluating Cost Benefits of Subcutaneous vs. Intravenous Trastuzumab/Pertuzumab in HER2-Positive Early Breast Cancer Patients: From Qatari Healthcare Perspective

    Dec 1, 2025, 00:00

  • HTA293 Role of Real-World Evidence (RWE) in Pricing and Reimbursement Decisions for Rare Disease in Health Technology Assessment (HTA) Submissions Across EU4 + UK

    Dec 1, 2025, 00:00

  • EPH225 Systematic Review on the Association of Loneliness and Social Isolation With Diabetes Mellitus

    Dec 1, 2025, 00:00

  • EPH264 Trends in the Number of Hospital Beds and Patient Turnover in Obstetrics and Gynecology in Hungary Between 2003 and 2023

    Dec 1, 2025, 00:00

  • EE318 Decision-Analytic Modeling on Imaging Modalities in Breast Cancer Staging: A Systematic Literature Review

    Dec 1, 2025, 00:00

  • P24 A Framework for Accelerating Clinical Development With Real-World External Control Arms (ECA) in Phase 2 Trials

    Dec 1, 2025, 00:00

  • P34 Carbon Footprint Associated With Severe Asthma Care Before and After Benralizumab Initiation: BENEFIT Study

    Dec 1, 2025, 00:00

  • EE487 Health Economic Analysis of Malnutrition in the Netherlands

    Dec 1, 2025, 00:00

  • EE168 Cost-Effectiveness of Belatacept as Conversion Therapy in the Management of Patients Living With a Renal Graft in France

    Dec 1, 2025, 00:00

  • CO11 Antibody-Drug Conjugates in Colorectal Cancer: A Scoping Review of Current Evidence and Emerging Clinical Trends

    Dec 1, 2025, 00:00

  • EE63 Assessing the Socioeconomic Value of Ocrelizumab Subcutaneous for Treating Relapsing Multiple Sclerosis in the Evolving Treatment Landscape in the United Kingdom

    Dec 1, 2025, 00:00

  • P8 Assessing the Full Life-Cycle Value of Highly Specialized Technologies and Advanced Therapy Medicinal Products in England

    Dec 1, 2025, 00:00

  • HTA255 NICE Reduces Waiting Times for Technology Adoption: Early Value Assessment As a Pragmatic Approach to Adopting Promising Innovation in the NHS

    Dec 1, 2025, 00:00

  • HPR109 Global Pricing Meets Domestic Policy: Analyzing the Financial Impact of the Most-Favored Nation Approach on the United States Medicine Prices

    Dec 1, 2025, 00:00

  • HPR79 Evolution in Hospital Bed Capacity in Hungary and Romania Between 1980 and 2020 With Special Focus on Regions Inhabited by Ethnic Minorities

    Dec 1, 2025, 00:00

  • MSR171 Prediction of Query Outcomes in the Setting of Observational Studies

    Dec 1, 2025, 00:00

  • EE10 A Cost-Effectiveness Analysis of First-Line Therapies for Microsatellite-Instability-High (MSI-H) or Mismatch-Repair-Deficient (dMMR) Unresectable or Metastatic Colorectal Cancer (mCRC) in France

    Dec 1, 2025, 00:00

  • HTA269 Paving the Path to Success for Joint Clinical Assessments: One Asset at a Time

    Dec 1, 2025, 00:00

  • RWD35 Clinical Relevance of a Machine Learning Model for Automated Analyses of Depression Severity: The ePHQ-9 in Treatment-Resistant Depression

    Dec 1, 2025, 00:00

  • HTA282 Recognizing the Full Value of Novel Antibiotics: Identifying Value Elements in the Context of Antimicrobial Resistance

    Dec 1, 2025, 00:00

  • PCR226 The EB Insights Study: The Impact of Epidermolysis Bullosa on Carer Health-Related Quality of Life

    Dec 1, 2025, 00:00

  • EPH255 The Role of Lifestyle in the Development of Fertility Issues

    Dec 1, 2025, 00:00

  • EE392 Economic Evaluations of Individual Service and Training Interventions for Self-Harm and Suicide Prevention: A Systematic Review

    Dec 1, 2025, 00:00

  • MSR81 Effect of Positive Airway Pressure Therapy on Mortality in European Obstructive Sleep Apnea Patients: Post Hoc Analysis of a Global Meta-Analysis

    Dec 1, 2025, 00:00

  • MT17 From Anxiety to Hope: Understanding the Adoption of AI Counseling Tools for Anxiety Management

    Dec 1, 2025, 00:00

  • CO257 Understanding XLH’s Impact: Incorporating Patient Perspectives to Develop a Comprehensive Conceptual Disease Model (CDM) to Drive Patient Engagement and the Generation of Meaningful Patient Experience Data

    Dec 1, 2025, 00:00

  • CO208 Real-World Outcomes From a Pharmacy-Based Awareness and Screening Campaign for HF and CKD: Insights From the Chronic Diseases From A to Z Program

    Dec 1, 2025, 00:00

  • PT7 The Association Between Average Sales Price Decline and Shortages in Small Molecule Injectable Oncology Therapies With Generic Competition

    Dec 1, 2025, 00:00

  • EE62 Assessing the Health-Related Quality of Life and Economic Burden of Dry Eye Disease in Thailand: A Multi-Center Study on Patient-Reported Outcomes

    Dec 1, 2025, 00:00

  • EPH276 Utility Values for Dementia in Finland and Spain

    Dec 1, 2025, 00:00

  • HTA102 Decoding the Future: How Are HTA Agencies Evaluating AI in Healthcare?

    Dec 1, 2025, 00:00

  • HTA204 Institutional Profiles and the Likelihood of Unfavorable Submissions in Public Consultations on Breast Cancer Drugs in Brazil’s Supplementary Health System

    Dec 1, 2025, 00:00

  • EE517 Healthcare Resource Utilization for Patients With Transthyretin Amyloid Cardiomyopathy: A Real-World Study in Europe, Canada, and Japan

    Dec 1, 2025, 00:00

  • PCR173 Patient Perspectives on Disease Experiences and Value of Real-Time Self-Reported Symptom and Treatment Monitoring in Locally Advanced and Metastatic Breast Cancer

    Dec 1, 2025, 00:00

  • EE415 Establishing Robust and Adaptive Willingness-to-Pay Thresholds for Taiwan's National Health Insuran A Case Study of Non-Small Cell Lung Cancer

    Dec 1, 2025, 00:00

  • HPR39 Budget Impact of Anakinra in Turkiye: An Analysis From the Social Security Institution’s Perspective

    Dec 1, 2025, 00:00

  • EE701 The Economic Burden of Moderate and Severe Anxiety and Depression Symptoms in Saudi Arabia

    Dec 1, 2025, 00:00

  • EE254 Cost-Effectiveness of High-Dose vs. Adjuvanted Trivalent Influenza Vaccines in Older Adults in Korea

    Dec 1, 2025, 00:00

  • EPH12 An Exploration of the Incidence Rate of Anxiety and Depression Following a Diagnosis of Osteoarthritis Using the THIN Dataset

    Dec 1, 2025, 00:00

  • EPH195 Psychotropic Medications to Patients With Treatment-Resistant Depression in France

    Dec 1, 2025, 00:00

  • MSR39 Assessing Bias in LLM-Extracted Real-World Data: A Health Equity Analysis of Access to Care and Outcomes in Metastatic Breast Cancer

    Dec 1, 2025, 00:00

  • P10 Advancing Lost Productivity Measurement in Economic Evaluations: Evidence Priorities From a Targeted Literature Review and Multi-Stakeholder Workshop

    Dec 1, 2025, 00:00

  • EPH43 Characterizing Polycystic Ovary Syndrome (PCOS) and Related Diagnoses Using a Large US Electronic Health Records Database Linked to Claims, 2020-2025

    Dec 1, 2025, 00:00

  • HSD46 Evaluating the Digital Transformation in Healthcare: Adoption, Challenges, and Opportunities

    Dec 1, 2025, 00:00

  • HTA112 Digital Health Technologies Assessment Based on Patient-Reported Outcome Measures (PROMs): Virtual Reality (VR) in the Treatment of Specific Phobias

    Dec 1, 2025, 00:00

  • EE244 Cost-Effectiveness of Delgocitinib vs. PUVA in Patients With Moderate-to-Severe Chronic Hand Eczema

    Dec 1, 2025, 00:00

  • MT23 Health Economic Evaluation Model for Breast Cancer Risk Management Through Preimplantation Genetic Testing for Monogenic Disorders (PGT-M)

    Dec 1, 2025, 00:00

  • RWD162 Real-World Patient Characteristics and Outcomes Associated With Antibody Drug Conjugate Therapy: A Large Cohort Study

    Dec 1, 2025, 00:00

  • CO252 Tocilizumab vs. Sarilumab Among Adults Hospitalized Due to COVID-19: A Federated Comparative Effectiveness Study Across England and Scotland Under the Target Trial Emulation Framework

    Dec 1, 2025, 00:00

  • PCR78 Establishing the Relationship Between the Worst Itch Numerical Rating Scale and EQ-5D Utility in Patients With Primary Biliary Cholangitis Experiencing Pruritus: Pooled Results From GLIMMER and the PRO Validation Study

    Dec 1, 2025, 00:00

  • EE85 Budget Impact Analysis of GLP-1 Receptor Agonists for Type 2 Diabetes Management in India

    Dec 1, 2025, 00:00

  • EE478 Foregone Net Monetary Benefit From Underdiagnosis and Undertreatment of Mild Cognitive Impairment Due to Alzheimer’s Disease in the Medicare Population

    Dec 1, 2025, 00:00

  • HPR171 Reframing Pharmaceutical Pricing: Implications of the 2025 SVR Report for Germany’s Pricing Logic and International Spillovers

    Dec 1, 2025, 00:00

  • PCR252 Triangulation Method to Detect Meaningful Deterioration in Patient's Autonomy Using the New Multiple Sclerosis Autonomy Scale (MSAS) Questionnaire

    Dec 1, 2025, 00:00

  • HTA223 Limited Access to Joint Scientific Consultations in 2025: Strategic Impact on Industry and Policy Directions for Sustainable EU HTA Implementation

    Dec 1, 2025, 00:00

  • EE398 Economic Impact of Faricimab in Neovascular Age-Related Macular Degeneration Management in France

    Dec 1, 2025, 00:00

  • SA50 How Much Time Does Artificial Intelligence Really Save in Evidence Synthesis? A Systematic Literature Review

    Dec 1, 2025, 00:00

  • EPH41 Characteristics Associated With Having an Activity of Daily Living Limitation (ADLL) or Instrumental Activity of Daily Living Limitation (IADLL) Among US Adults With Asthma

    Dec 1, 2025, 00:00

  • EPH246 The Incidence Mortality and Survival of Malignant Hematopoietic Neoplasms in the United States: A Surveillance, Epidemiology, and End Results (SEER) 2000-2022 Database Analysis

    Dec 1, 2025, 00:00

  • HPR2 A Case Study: How England Implemented Its First Population Health Agreement

    Dec 1, 2025, 00:00

  • CO170 Network Meta-Analysis for an Efficacy Assessment of Avelumab Axitinib in the First-Line Treatment of International Metastatic RCC Database Consortium (IMDC) Favorable Risk Patients With Advanced Renal Cell Carcinoma (ARCC)

    Dec 1, 2025, 00:00

  • PCR128 Impact of Cancer on the Burden of Caregiving in China, Japan, and EU5: National Health and Wellness Survey

    Dec 1, 2025, 00:00

  • RWD183 Transplant Eligibility in DLBCL: A Real-World Analysis of German Hospital Billing Data

    Dec 1, 2025, 00:00

  • EPH112 Food and Health Literacy Among University Students: Sociodemographic Insights

    Dec 1, 2025, 00:00

  • PT25 Systems-Level Modeling Approaches for Complex Health Technologies: A Systematic Review

    Dec 1, 2025, 00:00

  • HSD72 Mapping the Landscape of Digital Healthcare Services Delivered by Specialized Oncology Hospitals in China: Qualitative Analytical Study

    Dec 1, 2025, 00:00

  • HPR138 Market Access Challenges for Oncology Combination Therapies in Europe: A Review of Regulatory Approvals HTA Outcomes and Pricing Dynamics

    Dec 1, 2025, 00:00

  • EPH16 Analysis of the Epidemiological Disease Burden of Endometriosis in Hungary Based on Data From the Global Burden of Disease Study

    Dec 1, 2025, 00:00

  • EPH27 Beyond the Guidelines: Exploring the Characteristics and Comorbidity Profiles of Adults With Pneumococcal Disease in England Not Covered by Current Pneumococcal Vaccination Criteria

    Dec 1, 2025, 00:00

  • PCR56 Describing the Burden of RSV Infection and Subsequent Wheezing in Toddlers: An International Cross-Sectional Study

    Dec 1, 2025, 00:00

  • EE131 Clinical and Economic Impact of Hospital-Acquired Infections by Pseudomonas Aeruginosa in a Tertiary Care Teaching Hospital in India

    Dec 1, 2025, 00:00

  • EE416 Estimated Long-Term Healthcare Cost Savings From EVP Use in the UK

    Dec 1, 2025, 00:00

  • EE568 Long-Term Economic Impact of Nonpersistence to Disease-Modifying Therapies in a Cohort of German Patients With Multiple Sclerosis

    Dec 1, 2025, 00:00

  • EE140 Comparative Health Economic Evaluation of Alzheimer’s Diagnostic Treatment Strategies in the Era of Amyloid-Targeting Therapies: A Conceptual Model Framework

    Dec 1, 2025, 00:00

  • HTA317 The Growing Role of Real-World Evidence (RWE) to Support Efficacy in EMA Oncology Approvals: Light at the End of the Tunnel

    Dec 1, 2025, 00:00

  • EE386 Economic Evaluation of Synovial Biopsy-Guided Treatment Strategy After TNF-Alpha Inhibitor Failure in Rheumatoid Arthritis

    Dec 1, 2025, 00:00

  • EE495 Health Utilities Among Patients With Chronic Rhinosinusitis With Nasal Polyps: An Exploratory Analysis From the WAYPOINT Trial

    Dec 1, 2025, 00:00

  • RWD8 Accelerating HEOR Using Petri Net-Based Simulation Informed by Real-World Data

    Dec 1, 2025, 00:00

  • CO176 Pain-Related Disparities in Healthcare Expenditures Among Individuals With Cancer Evidence From the United States Medical Expenditure Panel Survey

    Dec 1, 2025, 00:00

  • HPR149 Negotiated Closed Budgets in Gree A Case Study of Success in Enhancing Patient Access Whilst Achieving Savings

    Dec 1, 2025, 00:00

  • HPR135 Managed Reimbursement of Continuous Glucose Monitoring Sensors in Ireland: Year One Review

    Dec 1, 2025, 00:00

  • HTA59 Budget Impact Analysis Of Migalastat Incorporation vs. Enzyme Replacement Therapies For Fabry Disease: Validation of a Cost-Assessment Tool In Brazilian Private Healthcare System

    Dec 1, 2025, 00:00

  • EE655 Saving Money Improving Outcomes: A Two-Year Cost-Utility Analysis of Emergency Department Care Models for Managing Persons Presenting With a Musculoskeletal Disorder

    Dec 1, 2025, 00:00

  • RWD153 Real-World Evidence in Action: Assessing Drug-Drug Interactions to Drive Value-Based Decisions

    Dec 1, 2025, 00:00

  • CO226 Systematic Literature Review (SLR) of First-Line (1L) Treatments of Patients With Advanced or Metastatic HER2-Positive Gastroesophageal Adenocarcinoma (GEA)

    Dec 1, 2025, 00:00

  • EE383 Economic Evaluation of Second-Generation Colon Capsule Endoscopy for Investigation of the Colon Through Direct Visualization

    Dec 1, 2025, 00:00

  • EE602 Optimizing Therapeutic Strategies for Multiple Sclerosis in Italy: A Budget Impact Analysis

    Dec 1, 2025, 00:00

  • EE307 Cost-Utility Analysis of Pegunigalsidase Alfa Compared to Agalsidase Alfa and Agalsidase Beta for the Treatment of Adult Patients With Fabry Disease in Greece

    Dec 1, 2025, 00:00

  • EPH29 Budget Impact of an Organized Cervical Cancer Screening in High-Risk Populations in France

    Dec 1, 2025, 00:00

  • SA44 From Participation to Partnership: Advancing Patient-Centric Inclusive and Equitable Evidence Generation in HEOR

    Dec 1, 2025, 00:00

  • RWD106 Influencing Factors on the Health-Related Quality of Life of Middle-Aged and Elderly People in Ethnic Minority Areas of China: An Analysis Based on the Survey in a Urban Community of Guangxi Province

    Dec 1, 2025, 00:00

  • PCR131 Impact of Nontransfusion-Dependent Thalassemia on Adult Patients' Health-Related Quality of Life and Work Productivity in the Kingdom of Saudi Arabia and United Arab Emirates

    Dec 1, 2025, 00:00

  • MSR172 Predictive Algorithms in HTA: What Factors Influence Decision Making in NICE, SMC, and NCPE?

    Dec 1, 2025, 00:00

  • MT45 Use of AI in Breast Cancer Screening in England Has a Minimal Impact on Greenhouse Gas Emissions and May Increase Diagnostic Accuracy

    Dec 1, 2025, 00:00

  • EE379 Economic Evaluation of Dinutuximab Beta in the Maintenance Therapy of High-Risk Neuroblastoma in Brazil

    Dec 1, 2025, 00:00

  • EPH212 Severity of COVID-19 Pre- and Post-Omicron Emergence in Pediatric Patients: A Global Systematic Literature Review

    Dec 1, 2025, 00:00

  • HPR7 A Decade of Change in Turkish Healthcare Utilization: Hospital Admission Trends 2015-2024

    Dec 1, 2025, 00:00

  • EE694 The Cost-Effectiveness of Targeted-Release Form (TRF)-Budesonide for the Treatment of Adult Population With Immunoglobulin A Nephropathy (IgAN) in Greece

    Dec 1, 2025, 00:00

  • PCR66 Domain Attrition in the IWQOL Series and the Challenges of Factor-Only Item Reduction

    Dec 1, 2025, 00:00

  • EE18 A Health Economic Evaluation Framework for Implementing a Digital Survivorship Passport for Childhood Cancer Survivors

    Dec 1, 2025, 00:00

  • CO209 Real-World Treatment Patterns and Outcomes in First-Line Small-Cell Lung Cancer (SCLC) in France

    Dec 1, 2025, 00:00

  • MSR111 From Complex Statistics to Clinically Meaningful Insights: Interpreting Results in Meta-Analyses of Continuous Outcomes

    Dec 1, 2025, 00:00

  • EE118 Burden of Illness and Healthcare Resource Utilization Among Patients Newly Diagnosed With Amyotrophic Lateral Sclerosis in the United States: A Retrospective, Observational, Cohort Design Study

    Dec 1, 2025, 00:00

  • HPR235 Utilization of Glucagon-Like Peptide-1 Receptor Agonists in the Irish Healthcare System

    Dec 1, 2025, 00:00

  • CO187 Preventing Bleeds in Pediatric Patients With Hemophilia A: Which Factor Replacement Therapy Offers the Best Protection and at What Cost?

    Dec 1, 2025, 00:00

  • RWD3 A Proof of Concept Study to Build a Japanese-Based Electronic Medical Record Data Model Suited for Real-World Research

    Dec 1, 2025, 00:00

  • HTA265 Patient Access Delays in Multi-Indication Medicines: A Review of Health Technology Assessment Timelines

    Dec 1, 2025, 00:00

  • PCR235 The Life With Amyotrophic Lateral Sclerosis: Socioeconomic Impact of the Disease on Patients and Their Caregivers in the Czech Republic

    Dec 1, 2025, 00:00

  • CO228 Systematic Literature Review of Artificial Intelligence-Based Models Predicting COPD Exacerbations

    Dec 1, 2025, 00:00

  • HTA45 Assessing the Cost-Effectiveness of Lecanemab for Early Alzheimer's Disease Treatment: A Swiss Perspective

    Dec 1, 2025, 00:00

  • HPR180 Science at PACE? A Multi-Stakeholder Developed Framework for Accelerated Patient Access to Cancer Care

    Dec 1, 2025, 00:00

  • HPR148 Navigating Three Systems: A Comparative Analysis of Pharmaceutical Reimbursement in Germany, Austria, and Switzerland

    Dec 1, 2025, 00:00

  • HPR156 Payer and HTA Evaluation Criteria and Considerations for Coverage and Reimbursement of Patient Self-Monitoring Technology

    Dec 1, 2025, 00:00

  • EE697 The Disease Burden of Systemic Sclerosis in the Russian Federation

    Dec 1, 2025, 00:00

  • EE464 Fecal Microbiota Transplantation for Irritable Bowel Syndrome With Constipation: A Decision-Analytical Analysis

    Dec 1, 2025, 00:00

  • MSR14 Advancing Multiple System Atrophy Diagnosis: Combining AI and Decision Analysis

    Dec 1, 2025, 00:00

  • PT21 Can Generative AI Deliver Patient-Friendly Summaries? A Case Study Using NICE Guidance for Spinal Muscular Atrophy

    Dec 1, 2025, 00:00
  • 1
  • 2
  • 3
  • 4
  • 5 (current)
  • 6
  • 7
  • 8
  • 9
  • 10
  • »